FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010060752> ?p ?o ?g. }

• W2010060752 endingPage "578" @default.
• W2010060752 startingPage "572" @default.
• W2010060752 abstract "Anemia in patients with end-stage renal disease (ESRD) is treated with recombinant human erythropoietin (rhEPO) often in combination with iron. However, iron catalyzes the formation of toxic radicals, which might promote vascular damage, is a nutrient for microorganisms, and negatively affects immune pathways, thus increasing the risk for severe infections.We investigated 28 patients on chronic hemodialysis who were randomized to receive either rhEPO alone (N = 15) or rhEPO in combination with intravenous iron (N = 13) for a period of 12 weeks. We analyzed iron therapy associated changes in cytokine patterns and endogenous radical formation.Tumor necrosis factor-alpha (TNF-alpha) levels were increased in ESRD patients at study entry and then decreased significantly over time in subjects receiving additional iron, while they increased with rhEPO alone. In contrast, we found serum concentrations of the anti-inflammatory cytokine interleukin (IL)-4 to increase with iron therapy. A significant negative correlation between iron availability, as determined by transferrin saturation, and TNF-alpha levels (P = 0.008) and a positive one between transferring saturation and IL-4 (P = 0.02) pointed to the potential role of iron to induce immunologic changes. Interestingly, iron therapy resulted in a slight decrease in the amounts of endogenous peroxides, which may be referred to reduced TNF-alpha concentrations since peroxide concentrations were positively correlated to TNF-alpha levels (P = 0.046) and negatively to transferrin saturation (P = 0.02).Iron supplementation in ESRD patients down-regulates proinflammatory immune effector pathways and stimulates the expression of the anti-inflammatory cytokine IL-4. Such a condition is detrimental for host response toward invading pathogens. However, tissue damage by radicals such as endogenous peroxides may be reduced in this condition due to impaired TNF-alpha formation." @default.
• W2010060752 created "2016-06-24" @default.
• W2010060752 creator A5016262504 @default.
• W2010060752 creator A5018269205 @default.
• W2010060752 creator A5018944198 @default.
• W2010060752 creator A5037779272 @default.
• W2010060752 creator A5048717328 @default.
• W2010060752 creator A5091766917 @default.
• W2010060752 date "2003-08-01" @default.
• W2010060752 modified "2023-09-26" @default.
• W2010060752 title "Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin" @default.
• W2010060752 cites W12810174 @default.
• W2010060752 cites W1681070212 @default.
• W2010060752 cites W1857052429 @default.
• W2010060752 cites W1976665224 @default.
• W2010060752 cites W1986604740 @default.
• W2010060752 cites W1991883054 @default.
• W2010060752 cites W1997923221 @default.
• W2010060752 cites W2010967452 @default.
• W2010060752 cites W2017828665 @default.
• W2010060752 cites W2018576224 @default.
• W2010060752 cites W2042015837 @default.
• W2010060752 cites W2044945923 @default.
• W2010060752 cites W2054976995 @default.
• W2010060752 cites W2065303599 @default.
• W2010060752 cites W2070168488 @default.
• W2010060752 cites W2070858375 @default.
• W2010060752 cites W2077619262 @default.
• W2010060752 cites W2082915790 @default.
• W2010060752 cites W2084357743 @default.
• W2010060752 cites W2086096523 @default.
• W2010060752 cites W2102983361 @default.
• W2010060752 cites W2108412323 @default.
• W2010060752 cites W2110509373 @default.
• W2010060752 cites W2132430482 @default.
• W2010060752 cites W2147825080 @default.
• W2010060752 cites W2150374661 @default.
• W2010060752 cites W2153916403 @default.
• W2010060752 cites W2170851607 @default.
• W2010060752 cites W2266086759 @default.
• W2010060752 cites W2298017524 @default.
• W2010060752 cites W2315613377 @default.
• W2010060752 cites W4241210960 @default.
• W2010060752 cites W4253440008 @default.
• W2010060752 doi "https://doi.org/10.1046/j.1523-1755.2003.00099.x" @default.
• W2010060752 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12846752" @default.
• W2010060752 hasPublicationYear "2003" @default.
• W2010060752 type Work @default.
• W2010060752 sameAs 2010060752 @default.
• W2010060752 citedByCount "97" @default.
• W2010060752 countsByYear W20100607522012 @default.
• W2010060752 countsByYear W20100607522013 @default.
• W2010060752 countsByYear W20100607522014 @default.
• W2010060752 countsByYear W20100607522015 @default.
• W2010060752 countsByYear W20100607522016 @default.
• W2010060752 countsByYear W20100607522017 @default.
• W2010060752 countsByYear W20100607522018 @default.
• W2010060752 countsByYear W20100607522020 @default.
• W2010060752 countsByYear W20100607522021 @default.
• W2010060752 countsByYear W20100607522022 @default.
• W2010060752 countsByYear W20100607522023 @default.
• W2010060752 crossrefType "journal-article" @default.
• W2010060752 hasAuthorship W2010060752A5016262504 @default.
• W2010060752 hasAuthorship W2010060752A5018269205 @default.
• W2010060752 hasAuthorship W2010060752A5018944198 @default.
• W2010060752 hasAuthorship W2010060752A5037779272 @default.
• W2010060752 hasAuthorship W2010060752A5048717328 @default.
• W2010060752 hasAuthorship W2010060752A5091766917 @default.
• W2010060752 hasBestOaLocation W20100607521 @default.
• W2010060752 hasConcept C126322002 @default.
• W2010060752 hasConcept C134018914 @default.
• W2010060752 hasConcept C153852466 @default.
• W2010060752 hasConcept C164027704 @default.
• W2010060752 hasConcept C17991360 @default.
• W2010060752 hasConcept C203014093 @default.
• W2010060752 hasConcept C2776768029 @default.
• W2010060752 hasConcept C2776914184 @default.
• W2010060752 hasConcept C2777417653 @default.
• W2010060752 hasConcept C2778248108 @default.
• W2010060752 hasConcept C2778319317 @default.
• W2010060752 hasConcept C2778534260 @default.
• W2010060752 hasConcept C2778690821 @default.
• W2010060752 hasConcept C2779875672 @default.
• W2010060752 hasConcept C71924100 @default.
• W2010060752 hasConcept C8891405 @default.
• W2010060752 hasConceptScore W2010060752C126322002 @default.
• W2010060752 hasConceptScore W2010060752C134018914 @default.
• W2010060752 hasConceptScore W2010060752C153852466 @default.
• W2010060752 hasConceptScore W2010060752C164027704 @default.
• W2010060752 hasConceptScore W2010060752C17991360 @default.
• W2010060752 hasConceptScore W2010060752C203014093 @default.
• W2010060752 hasConceptScore W2010060752C2776768029 @default.
• W2010060752 hasConceptScore W2010060752C2776914184 @default.
• W2010060752 hasConceptScore W2010060752C2777417653 @default.
• W2010060752 hasConceptScore W2010060752C2778248108 @default.
• W2010060752 hasConceptScore W2010060752C2778319317 @default.
• W2010060752 hasConceptScore W2010060752C2778534260 @default.
• W2010060752 hasConceptScore W2010060752C2778690821 @default.

• next